A closer look at reported colitis in association with multiple sclerosis treatments

Abstract

Get full access to this article

View all access options for this article.

References

Kim

Brinker

Croteau

, et al. Immune-mediated colitis associated with ocrelizumab: A new safety risk. Mult Scler J 2023; 29(10): 1275–1281.

OCREVUS® (ocrelizumab) injection, for intravenous use initial U.S. approval: 2017, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761053s029s030lbl.pdf

Kosmidou

Katsanos

, et al. Multiple sclerosis and inflammatory bowel diseases: A systematic review and meta-analysis. J Neurol 2017; 264(2): 254–259.

Abboud

. Colitis in ocrelizumab-treated patients: The dilemma of causation versus association in immune-mediated iatrogenicity. Mult Scler J 2023; 29(10): 1201–1203.